Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice

Abstract Ankylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM)...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Hyemin Jeong, In Young Kim, Eun-Kyung Bae, Chan Hong Jeon, Kwang-Sung Ahn, Hoon-Suk Cha
Formato:	article
Lenguaje:	EN
Publicado:	Nature Portfolio 2021
Materias:	Medicine R Science Q
Acceso en línea:	https://doaj.org/article/f3775273384340769ff490c63ac2abe0
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:f3775273384340769ff490c63ac2abe0
record_format	dspace
spelling	oai:doaj.org-article:f3775273384340769ff490c63ac2abe02021-12-02T17:52:23ZSelective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice10.1038/s41598-021-91320-12045-2322https://doaj.org/article/f3775273384340769ff490c63ac2abe02021-06-01T00:00:00Zhttps://doi.org/10.1038/s41598-021-91320-1https://doaj.org/toc/2045-2322Abstract Ankylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.Hyemin JeongIn Young KimEun-Kyung BaeChan Hong JeonKwang-Sung AhnHoon-Suk ChaNature PortfolioarticleMedicineRScienceQENScientific Reports, Vol 11, Iss 1, Pp 1-12 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine R Science Q
spellingShingle	Medicine R Science Q Hyemin Jeong In Young Kim Eun-Kyung Bae Chan Hong Jeon Kwang-Sung Ahn Hoon-Suk Cha Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
description	Abstract Ankylosing spondylitis is a male-predominant disease and previous study revealed that estrogens have an anti-inflammatory effect on the spondyloarthritis (SpA) manifestations in zymosan-induced SKG mice. This study aimed to evaluate the effect of selective estrogen receptor modulator (SERM) lasofoxifene (Laso) on disease activity of SpA. Mice were randomized into zymosan-treated, zymosan + 17β-estradiol (E2)-treated, and zymosan + Laso-treated groups. Arthritis was assessed by 18F-fluorodeoxyglucose (18F-FDG) small-animal positron emission tomography/computed tomography and bone mineral density (BMD) was measured. Fecal samples were collected and 16S ribosomal RNA gene sequencing was used to determine gut microbiota differences. Both zymosan + E2-treated mice and zymosan + Laso-treated mice showed lower arthritis clinical scores and lower 18F-FDG uptake than zymosan-treated mice. BMD was significantly higher in zymosan + E2-treated mice and zymosan + Laso-treated mice than zymosan-treated mice, respectively. Fecal calprotectin levels were significantly elevated at 8 weeks after zymosan injection in zymosan-treated mice, but it was not significantly changed in zymosan + E2-treated mice and zymosan + Laso-treated mice. Gut microbiota diversity of zymosan-treated mice was significantly different from zymosan + E2-treated mice and zymosan + Laso-treated mice, respectively. There was no significant difference in gut microbiota diversity between zymosan + E2-treated mice and zymosan + Laso -treated mice. Laso inhibited joint inflammation and enhanced BMD in SKG mice, a model of SpA. Laso also affected the composition and biodiversity of gut microbiota. This study provides new knowledge regarding that selected SpA patients could benefit from SERM treatment.
format	article
author	Hyemin Jeong In Young Kim Eun-Kyung Bae Chan Hong Jeon Kwang-Sung Ahn Hoon-Suk Cha
author_facet	Hyemin Jeong In Young Kim Eun-Kyung Bae Chan Hong Jeon Kwang-Sung Ahn Hoon-Suk Cha
author_sort	Hyemin Jeong
title	Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
title_short	Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
title_full	Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
title_fullStr	Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
title_full_unstemmed	Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice
title_sort	selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced skg mice
publisher	Nature Portfolio
publishDate	2021
url	https://doaj.org/article/f3775273384340769ff490c63ac2abe0
work_keys_str_mv	AT hyeminjeong selectiveestrogenreceptormodulatorlasofoxifenesuppressesspondyloarthritismanifestationandaffectscharacteristicsofgutmicrobiotainzymosaninducedskgmice AT inyoungkim selectiveestrogenreceptormodulatorlasofoxifenesuppressesspondyloarthritismanifestationandaffectscharacteristicsofgutmicrobiotainzymosaninducedskgmice AT eunkyungbae selectiveestrogenreceptormodulatorlasofoxifenesuppressesspondyloarthritismanifestationandaffectscharacteristicsofgutmicrobiotainzymosaninducedskgmice AT chanhongjeon selectiveestrogenreceptormodulatorlasofoxifenesuppressesspondyloarthritismanifestationandaffectscharacteristicsofgutmicrobiotainzymosaninducedskgmice AT kwangsungahn selectiveestrogenreceptormodulatorlasofoxifenesuppressesspondyloarthritismanifestationandaffectscharacteristicsofgutmicrobiotainzymosaninducedskgmice AT hoonsukcha selectiveestrogenreceptormodulatorlasofoxifenesuppressesspondyloarthritismanifestationandaffectscharacteristicsofgutmicrobiotainzymosaninducedskgmice
_version_	1718379262881300480

Selective estrogen receptor modulator lasofoxifene suppresses spondyloarthritis manifestation and affects characteristics of gut microbiota in zymosan-induced SKG mice

Ejemplares similares